Single DermaVir Immunization in HIV-1 Infected Patients on HAART

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
HIV Infection
Interventions
BIOLOGICAL

DermaVir

DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.

DRUG

HAART

Three or more antiretroviral drugs that can fully suppress HIV RNA

Trial Locations (1)

1097

Saint Laszlo Hospital, Budapest

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genetic Immunity

INDUSTRY